Clinical Trials Browser

Phase 3 × trastuzumab deruxtecan × 30 days × Clear all

Breast Neoplasms

NCT07022483 2026-05-28

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Phase 3 Recruiting

710 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

490 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT07578116 2026-05-27

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

Phase 3 Not yet recruiting

562 enrolled

Breast

Anatomic Stage IV Breast Cancer AJCC v8

NCT06819007 2026-05-26

DO-01

Phase 3 Recruiting

582 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Phase 3 Active not recruiting

1,157 enrolled 1 FDA

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT04622319 2026-05-15

DESTINY-Breast05

Phase 3 Active not recruiting

1,600 enrolled 1 FDA

Breast

HER2-Positive Primary Breast Cancer

NCT06467357 2026-05-14

DESTINY-BTC01

Phase 3 Recruiting

620 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04739761 2026-05-12

DESTINY-B12

Phase 3 Active not recruiting

506 enrolled 27 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06764875 2026-05-12

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3 Recruiting

840 enrolled

Gastrointestinal

HER2-positive Gastric Cancer

NCT06989112 2026-05-06

DE-01

Phase 3 Recruiting

600 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

Clinical Trials

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

DO-01

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

DESTINY-Breast05

DESTINY-BTC01

DESTINY-B12

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

DE-01